Charles Schwab
OLMA icon

Charles Schwab’s Olema Pharmaceuticals OLMA Stock Holding History

Charles Schwab’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.48M Buy
518,342
+51,796
+11% +$694K ﹤0.01% 2352
2026
Q1 		$6.96M Buy
466,546
+59,405
+15% +$1.32M ﹤0.01% 2254
2025
Q4 		$10.2M Buy
407,141
+12,014
+3% +$214K ﹤0.01% 2136
2025
Q3 		$3.87M Sell
395,127
-35,395
-8% -$213K ﹤0.01% 2538
2025
Q2 		$1.83M Buy
430,522
+81,499
+23% +$363K ﹤0.01% 2692
2025
Q1 		$1.31M Buy
349,023
+16,073
+5% +$80.8K ﹤0.01% 2747
2024
Q4 		$1.94M Buy
332,950
+2,189
+0.7% +$21.9K ﹤0.01% 2688
2024
Q3 		$3.95M Buy
330,761
+207,565
+168% +$2.65M ﹤0.01% 2484
2024
Q2 		$1.33M Buy
123,196
+36,239
+42% +$393K ﹤0.01% 2834
2024
Q1 		$984K Sell
86,957
-2,253
-3% -$29.1K ﹤0.01% 2800
2023
Q4 		$1.25M Buy
89,210
+9,258
+12% +$124K ﹤0.01% 2764
2023
Q3 		$987K Hold
79,952
– – ﹤0.01% 2803
2023
Q2 		$722K Buy
79,952
+61,372
+330% +$371K ﹤0.01% 2886
2023
Q1 		$64.5K Hold
18,580
– – ﹤0.01% 3306
2022
Q4 		$45.5K Hold
18,580
– – ﹤0.01% 3378
2022
Q3 		$52K Sell
18,580
-118,686
-86% -$503K ﹤0.01% 3324
2022
Q2 		$559K Sell
137,266
-54,265
-28% -$172K ﹤0.01% 3034
2022
Q1 		$816K Sell
191,531
-11,079
-5% -$61.1K ﹤0.01% 2932
2021
Q4 		$1.9M Buy
202,610
+6,586
+3% +$136K ﹤0.01% 2718
2021
Q3 		$5.4M Buy
196,024
+114,590
+141% +$3.09M ﹤0.01% 2336
2021
Q2 		$2.28M Buy
81,434
+2,818
+4% +$80.2K ﹤0.01% 2673
2021
Q1 		$2.61M Buy
+78,616
New +$3.37M ﹤0.01% 2587

Other funds holding OLMA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Charles Schwab's OLMA Position: Q2 2026 in Review

Charles Schwab increased its Olema Pharmaceuticals (OLMA) stake by 11% in Q2 2026, buying an estimated $694K and bringing the position to 518,342 shares worth $6.48M. The position accounts for ﹤0.01% of the portfolio, ranked #2352.

Charles Schwab first reported a position in OLMA in Q1 2021 and has held it in 22 quarters since. The position peaked at $10.2M in Q4 2025. 185 funds tracked by Wall St. Rank hold OLMA as of Q2 2026.

  • Charles Schwab held 518,342 shares of Olema Pharmaceuticals worth $6.48M as of Q2 2026.
  • Charles Schwab bought 51,796 Olema Pharmaceuticals shares in Q2 2026, an estimated $694K.
  • Olema Pharmaceuticals made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #2352 holding.
  • Charles Schwab first reported a position in Olema Pharmaceuticals in Q1 2021 and has held it in 22 quarters since.
  • Charles Schwab's Olema Pharmaceuticals position peaked at $10.2M in Q4 2025.
  • 185 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.